RTTNews | Oct 25, 2021 07:54AM EDT

07:54 Monday, October 25, 2021 (RTTNews.com) - Merck & Co., Inc. (MRK) announced positive results from two pivotal Phase 3 trials of the investigational, once-daily oral fixed dose combination pill of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection who are virologically suppressed on different antiretroviral therapy regimens or bictegravir/emtricitabine/tenofovir.

The company noted that week 48 data met safety and efficacy endpoints in adults with HIV-1 infection currently on antiretroviral therapy. The safety and tolerability profile of DOR/ISL during the trials to date are consistent with the previously reported Phase 2 studies.

Doravirine is approved for the treatment of adults with HIV-1 in combination with other antiretrovirals, as a single agent (PIFELTRO) and a component of a single-tablet regimen.

Islatravir is Merck's investigational nucleoside reverse transcriptase translocation inhibitor under evaluation for the treatment of people living with HIV-1 infection in combination with other antiretrovirals.

Read the original article on RTTNews ( https://www.rttnews.com/3235103/merck-positive-results-from-phase-3-trial-of-doravirine-islatravir-for-hiv-1-infection-treatment.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved